It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
The impacts of high density lipoprotein cholesterol (HDL‐C) as an anti‐inflammatory and C reactive protein (CRP) as inflammatory properties on the pathogenesis of heart failure were reported. At present, the clinical significance of the HDL‐C/CRP ratio in heart failure with preserved ejection fraction (HFpEF) patients remains unknown.
Methods and results
We examined the data on 796 consecutive HFpEF (left ventricular ejection fraction ≥50%) patients hospitalized due to acute decompensated heart failure from the PURSUIT‐HFpEF registry, a prospective, multicentre observational study. We calculated the HDL/CRP ratios and evaluated the relationship between the values and clinical outcomes, including degree of cardiac function. The mean follow‐up duration was 420 ± 346 days. All‐cause death occurred in 118 patients, of which 51 were cardiac deaths. HDL/CRP ≤ 4.05 was independently and significantly associated with all‐cause death (odds ratio = 1.84, 95% CI: 1.06–3.20, P = 0.023), and HDL/CRP ≤ 3.14 was associated with cardiac death by multivariate Cox proportional hazard analysis (odds ratio = 2.86, 95% CI: 1.36–6.01, P = 0.003). HDL‐C/CRP ratio significantly correlated with the product of the left atrial volume and left ventricular mass index as well as the tricuspid annular plane systolic excursion by multiple regression analysis (standardized beta‐coefficient = −0.085, P = 0.034 and standardized beta‐coefficient = 0.081, P = 0.044, respectively).
Conclusions
HDL‐C/CRP ratio was a useful marker for predicting all‐cause death and cardiac death and correlated with left ventricular diastolic function and right ventricular systolic function in HFpEF patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ukita, Kohei 1 ; Kawamura, Akito 1 ; Nakamura, Hitoshi 1 ; Matsuhiro, Yutaka 1 ; Yasumoto, Koji 1 ; Tsuda, Masaki 1 ; Okamoto, Naotaka 1 ; Tanaka, Akihiro 1 ; Matsunaga‐Lee, Yasuharu 1 ; Egami, Yasuyuki 1 ; Shutta, Ryu 1 ; Tanouchi, Jun 1 ; Yamada, Takahisa 2 ; Yasumura, Yoshio 3 ; Tamaki, Shunsuke 2 ; Hayashi, Takaharu 4 ; Nakagawa, Akito 5 ; Nakagawa, Yusuke 6 ; Suna, Shinichiro 7 ; Nakatani, Daisaku 7 ; Hikoso, Shungo 7 ; Sakata, Yasushi 7 1 Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan
2 Division of Cardiology, Osaka General Medical Center, Osaka, Japan
3 Division of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan
4 Cardiovascular Division, Osaka Police Hospital, Osaka, Japan
5 Division of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan, Department of Medical Informatics, Osaka University Graduate School of Medicine, Suita, Japan
6 Division of Cardiology, Kawanishi City Hospital, Kawanishi, Japan
7 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan





